Cargando…
Co-aerosolized Pulmonary Surfactant and Ambroxol for COVID-19 ARDS Intervention: What Are We Waiting for?
After more than 225 days of the first reports of the novel coronavirus from China, COVID-19 pandemic is still on surge. The search for an effective and efficient therapeutic and pharmaceutical intervention is as important and urgent now as it was on Day 1. Majority of the efforts in this direction a...
Autor principal: | Kumar, Pradeep |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7546362/ https://www.ncbi.nlm.nih.gov/pubmed/33102461 http://dx.doi.org/10.3389/fbioe.2020.577172 |
Ejemplares similares
-
Pulmonary Surfactant and Drug Delivery: An Interface-Assisted Carrier to Deliver Surfactant Protein SP-D Into the Airways
por: García-Mouton, Cristina, et al.
Publicado: (2021) -
Silver nanoparticles with excellent biocompatibility block pseudotyped SARS-CoV-2 in the presence of lung surfactant
por: Gupta, Govind, et al.
Publicado: (2022) -
Humidified and Heated Cascade Impactor for Aerosol Sizing
por: Majoral, Caroline, et al.
Publicado: (2020) -
Aerosol Test Chambers: Current State and Practice During the COVID-19 Pandemic
por: Yeh, Kenneth B., et al.
Publicado: (2022) -
Corrigendum: Aerosol test chambers: Current state and practice during the COVID-19 pandemic
por: Yeh, Kenneth B., et al.
Publicado: (2022)